AbbVie Reports Second-Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
UPDATE: AbbVie (ABBV) Guides Q3 EPS Below Views
July 24, 2015 9:37 AM EDT(Updated - July 24, 2015 9:45 AM EDT)
AbbVie (NYSE: ABBV) sees Q3 EPS of 1.05 - $1.07, with estimates at $1.09.
... MoreAbbVie (ABBV) Tops Q2 EPS by 2c
July 24, 2015 7:53 AM EDTAbbVie (NYSE: ABBV) reported Q2 EPS of $1.08, $0.02 better than the analyst estimate of $1.06. Revenue for the quarter came in at $5.48 billion versus the consensus estimate of $5.62 billion.
Key Events from the Second Quarter
On May 26, AbbVie successfully completed the acquisition of Pharmacyclics, accelerating AbbVie's clinical and commercial presence in oncology. The acquisition aligns strategically to AbbVie's business model, strengthening the company's already robust oncology pipeline and further diversifying AbbVie's revenue base.AbbVie announced that the European Commission granted marketing authorization for IMBRUVICA (ibrutinib) as the first treatment option specifically... More